The log-rank test is most powerful under proportional hazards (PH). In practice, non-PH patterns are often observed in clinical trials, such as in immuno-oncology; therefore, alternative methods are needed to restore the efficiency of statistical testing. Three categories of testing methods were evaluated, including weighted log-rank tests, Kaplan-Meier curve-based tests (including weighted Kaplan-Meier and Restricted Mean Survival Time, RMST), and combination tests (including Breslow test, Lee's combo test, and MaxCombo test). Nine scenarios representing the PH and various non-PH patterns were simulated. The power, type-I error, and effect estimates of each method were compared. In general, all tests control type I error well. There is not a single most powerful test across all scenarios. In the absence of prior knowledge regarding the PH or non-PH patterns, the MaxCombo test is relatively robust across patterns. Since the treatment effect changes overtime under non-PH, the overall profile of the treatment effect may not be represented comprehensively based on a single measure. Thus, multiple measures of the treatment effect should be pre-specified as sensitivity analyses to evaluate the totality of the data.
INTRODUCTION
Time-to-event outcomes are often used as the primary endpoint for clinical trials in many disease areas. Most randomized controlled trials with a time-to-event outcome are designed and analyzed using the log-rank test and the Cox model under the assumption of proportional hazards. The log-rank p-value evaluates the statistical significance of the treatment effect, and the hazard ratio (HR) from the Cox model is used to quantify such effect. The log-rank test is most powerful and the Cox model provides unbiased HR estimates under proportional hazards (PH). However, under non-proportional hazards (non-PH), the log-rank test loses power and interpretation of the HR becomes challenging. In practice, the PH assumption is restrictive and for various reasons non-proportional hazards (non-PH) are often observed in clinical trials. In particular, patterns of delayed treatment effects have been observed recently across immuno-oncology trials. There could be multiple underlying causes for the delayed treatment effects, for example, the unique mechanism of action of the treatment, heterogeneous underlying population subgroups, and study design. Log-rank test is still statistically valid under non-PH, but it often suffers from substantial power loss. To mitigate the power loss, an increase in the sample size and/or a delay in study readout is needed, which often delays the availability of the therapy to patients with unmet medical needs. Alternative tests and estimation methods under non-PH for primary analysis may reduce false negative results whilst maintaining control of false positive rate and provide more comprehensive description of the treatment effect. They may also shorten the study duration as well as the time to bring new treatments to patients,
The most common types of non-PH, in the order of importance, are delayed treatment effects, crossing hazards, and diminishing treatment effects over time. A wide range of statistical methods for analyzing time-to-event data with different types of non-PH are discussed in the literature notably weighted log-rank tests (e.g., Fleming and Harrington 1981) , weighted Kaplan- Meier tests (Pepe and Fleming 1991) , restricted mean survival time comparisons (Royston and Parmar 2013), and combination tests (Breslow, et al. 1984 and Logan, et al. 2008) . While there may be hypotheses about the exact nature of treatment effects at the stage of study design, we have found that such assumption is often times speculative and sometimes woefully inaccurate.
This poses an additional challenge while choosing the primary analysis at the design stage of a trial with potential non-PH. Therefore, a test for the primary analysis is needed that is robust under different types of non-PH scenarios. In this paper we focus on three categories of methods as potential candidates for primary analysis.
The first category of methods includes the weighted version of the log-rank test which considers certain time periods more relevant than others. For instance, in immuno-oncology where there is a delayed treatment effect, events observed at later time points may be more precisely representing the full treatment benefit compared to the events observed at earlier time points. We have considered the Fleming-Harrington ( ( , )) class of weighted log-rank tests. For many given underlying assumptions on treatment effects, appropriate selection of and can provide a well-powered test by varying weights appropriately over time. The second category includes tests based on the Kaplan-Meier curve. We consider the weighted Kaplan-Meier (WKM) test and restricted mean survival time (RMST) comparisons which has gained significant attention in recent years. Finally, we consider a set of combination tests which is an adaptive procedure to select the best test from a small pre-specified set of test statistics, including multiplicity correction. In this paper we outline these three categories of test statistics and compare their operating characteristics via simulation studies.
METHODS

Weighted Log-rank Tests
Weighted log-rank test statistics take the form of the weighted sum of the differences of the estimated hazard functions at each observed failure time. As a result, these statistics are used to test whether the hazard difference is zero between the treatment group and the control group. In the non-PH setting, the relative differences of the two hazard functions are not constant over time, therefore a differential weighting (compared to equal weighting in the log-rank statistic) at different time points has the potential to improve the efficiency of the test statistics. In this simulation study, we are particularly interested in the Fleming-Harrington family of weighted log-rank test statistics, commonly denoted as FH( , ) = ( −) (1 − ( −)) , , ≥ 0.
FH(0,0) is the log-rank statistic that is most powerful under the proportional hazards assumption; when this is a diminishing effect (i.e. early separation), FH( , 0) with > 0 that over weights the early events will provide higher power to detect a treatment difference compared with equal weighting; on the contrary, when delayed effect exists, FH(0, ) with > 0 that over weights the late events will be more powerful to detect the late separation; and FH( , ) with = > 0 will be more powerful if the biggest separation of two hazard functions occurs in the middle.. The weights in the weighted log-rank tests can be incorporated into the Cox model to provide a HR estimate of the "weighted" treatment effect (Sasieni 1993) or to provide a HR estimate of the "full" treatment effect together with a time-varying effect profile (Lin 2017 ). If one assumes the log-hazard ratio takes the form Φ( ), where Φ( ) is a known function, then the score test for = 0 will reduce to a weighted log-rank statistic with weight equal to Φ( ) (Lin 2017). This weight is optimal and achieves the highest testing power if the assumed hazard ratio is correct (Schoenfeld 1981 ).
Weighted Kaplan-Meier Tests
Weighted Kaplan-Meier tests take the form of the weighted sum of the differences of the Kaplan-Meier estimates (Kaplan and Meier, 1958) of survival functions. Therefore, they are valid to test whether the two underlying survival functions are the same or not. A particularly interesting weighted Kaplan-Meier test is Fleming, 1989, 1991) to set the weight equal to 1, resulting in the difference of two RMSTs (Uno et al. 2015 , Zhao et al. 2016 ).
Combination Tests
A new set of test statistics may be derived by combining some members within a class and/or across classes. This is potentially useful in the presence of non-PH. In this comparison study, we are mainly interested in the maximum combination (MaxCombo) using the Fleming-Harrington weight family FH(ρ, γ), ρ, γ ≥ 0 test statistics, which takes the form:
where Z FH(ρ,γ) is the standardized Fleming-Harrington weighted log-rank statistics. In particular, we are interested in the combination of FH(0,0), FH(0,1), FH(1,1) and FH(1,0), which should be sensitive to PH, late-separation, middle-separation and early-separation scenarios (Fine 2007) .
A similar combination method incorporating only FH(0,1) and FH(1,0) was proposed by Lee (Lee 2007 We included the Breslow test because of its potential power gain under crossing hazards.
A more detailed description of methods, along with relevant references, can be found in Appendix I.
SIMULATION STUDIES
Simulation Study Design
In this simulation study, we used piece-wise exponential models to generate simulated data with parameters calibrated based on real trial data in order to represent common non-PH patterns, such as delayed treatment effects, diminishing treatment effects and crossing hazards, regardless of the underlying causes that can be challenging to identify. Despite the simplicity of the piecewise exponential distribution, data simulated from these distributions mimic observed trial results quite closely suggesting that the performance of the analysis methods evaluated in this simulation study would be relevant in real studies.
All simulated trials described here equally allocated patients to an experimental arm (E) and a control arm (C). Survival data for both arms in all trials were simulated from piece-wise exponential distributions with one change point in the hazard function. The hazard change point was set as the same for the experimental arm and the control arm throughout the study. To be specific, let λC(t) and λE(t) denote the hazard functions, CP denote the change point, and λCj and λEj denote the hazard rates for the control arm and experimental arm respectively, where j=1 refers to the period before the change point and j=2 refers to that after the change point. The hazard functions considered in this study can be specified as λC(t)= λC1*1{0 ≤ t < CP} + λC2*1{t ≥ CP} and λE(t)= λE1*1{0 ≤ t < CP} + λE2*1{t ≥ CP}. The piece-wise hazard ratio HRj = λEj/ λCj was used to define the treatment effect for the jth period.
Nine scenarios were considered: seven non-PH scenarios (two Delayed effects, one Diminishing effects, and two Crossing hazards, two Delayed effect with converging tails), one scenario in which the PH assumption holds, and one null scenario in which there is no treatment difference.
To better illustrate survival kinetics, survival functions from each scenario except for the null scenario are displayed in Figure 1 . The parameters used to simulate data for each scenario are included in Table 1 .
The first five non-PH scenarios have one change point, therefore, two pieces of hazard ratios that take different values. In the Delayed effect scenario 1, the experimental and control arms have almost identical hazards (HR1=0.99) before 3 months, and the hazard decreases for the experimental arm but increases for the control arm (HR2=0.478) after 3 months. The experimental and control arms in the Delayed effect scenario 2 also have similar hazard (HR1=0.929) before 3 months, but the hazards before change point are higher than that in scenario 1, suggesting more events will occur in the first 3 months in scenario 2 compared with scenario 1. After 3 months, the hazard for the control arm remains the same while hazard for the experimental arm decreases substantially (HR2=0.356).
In the Diminishing effect scenario, the treatment is effective (constant HR1=0.731) within the first 6 months, but then the treatment effect disappears (HR2=0.979) after change point. Crossing hazards scenarios 1 and 2 represent situations in which the favorable treatment changes from the control arm to the experimental arm before and after the change point, leading to the hazard ratio changing from HR1>1 to HR2<1.
In the last two non-PH scenarios, Delayed effect with converging tails scenarios 1 and 2, there are two change points with three distinct hazard ratios, representing scenarios where there is no treatment effect in the beginning of the treatment period, then treatment benefit emerges in in the middle of the treatment period (i.e., delayed effect), and later the effect diminishes again, resulting in converging tails of survival curves.
The Proportional hazard scenario, where the proportional hazard assumption holds (HR1=HR2=0.68), is included in the study to compare all methods where the standard log-rank test is optimal (most powerful).
The Null scenario (HR1=HR2=1) is included to evaluate whether each method preserves the type I error rate.
It is well-known that the total number of events plays a key role in survival analysis, and the analysis of a study is often triggered when a pre-specified number of events is reached. However, study enrollment, drop out, and sample size may also impact the analysis. To explore the impact on the testing power by the event-patient ratios (i.e., number of events divided by sample size), enrollment, and drop out, we fixed the total number of events at 210 events and considered various sample sizes, event rates, and enrolment patterns. Three sample sizes 300, 600, and 1200 (or correspondingly, three event rates 70%, 35%, and 17.5%), with three enrollment patterns were explored, resulting in a total of 9 cases within each scenario. Drop-out time is assumed to be independent of the events and follow an exponential distribution with a hazard rate of 0.014.
When a total of 210 events had occurred, a data cut (i.e., administrative censoring) was applied and data were analyzed using each method.
For each of the three sample sizes, three enrollment durations were considered, namely 12, 18, and 24 months of overall enrollment duration, including a 6-month ramp-up period.
To obtain a more precise estimate of the type I error, 20,000 trial datasets were simulated for each case in the Null scenario. For all other scenarios, 5,000 trial datasets were simulated.
Hypothesis testing was conducted at the one-sided 2.5% significance level, and the power of each testing method was summarized. For weighted log-rank, Lee's method and MaxCombo tests, the HR estimates for the "weighted averaged" effect (Sasieni 1991) were also reported.
The simulations and analyses were conducted using the nphsim package in R (Wang et al. 2018 ).
Simulation Results
Type I Error
All nine tests under the null hypothesis of no treatment group difference control overall type I error well across the combinations of sample size and enrollment pattern. Table 2 shows the results from the 18-month enrollment pattern and similar results were observed in the 12-month and the 24-month enrollment patterns, for which the results were included in Appendix III.
Random spikes over 2.5% are mostly within simulation standard error, which is 0.1% based on 20,000 random samples. For sample sizes of 600 and 1200, the overall type I errors for the Breslow combo test tend to be much smaller, between 1.0% and 1.5%, due to the conservative nature of that test assuming asymptotic independence between component tests. points, and therefore its performance is impacted by the diminishing effect. In the cases with low event-patient ratio (e.g., sample size of 1200), the diminishing effect appears to have limited impact on the performance of FH(0,1), Lee's and RMST because the diminishing effect is not yet observed due to the short follow-up time.
Additional observations on the effects of event-patient ratio (analysis timing) and enrollment pattern
Note that in the delayed effect and crossing effect scenarios, all methods have higher power in simulated studies with 300 patients (70% event rate) compared to those with 1200 patients (17.5% event rate). This is mainly because the analysis is driven by a fixed number of events (210 events) and therefore studies with smaller sample size will have higher event-patient ratios (which includes more late events). The more mature data are able to reflect the treatment benefit after the delayed period, which increases the power. In contrast, in the diminishing effect scenario, the power increases when the sample size increases because simulated studies with larger sample size include mainly early events when the treatment effect is stronger and thus have higher power across all methods. In the PH scenario, sample size does not impact the power since the treatment effect is constant over time and thus the power mainly depends on the number of events. On the other hand, the hazard ratio is constant over time under the PH scenario, therefore the power depends only on the number of events and is similar across various event-patient ratios.
Enrollment pattern has minimal impact on the performance of the tests based on the 3 enrollment patterns simulated in this study.
Hazard Ratio Estimation
One way to report the treatment effect estimate when using the weighted log-rank test and the MaxCombo test is through the "weighted" HR estimated from the corresponding weighted Cox model (Sasieni 1993 ). The geographic means of these HR estimates are summarized in Table 3 (based on the 18-month enrollment pattern; similar results were observed for the 12-month and the 24-month enrollment patterns). For PH scenarios (including null), the estimates of HR from the Cox model are unbiased, whereas the estimates of HR from the MaxCombo are slightly lower; 0.94-0.95 versus 1 for the null case and 0.65 versus true 0.68 for the PH case, respectively.
This slight bias (anti-conservative) is due to the model selection inherent in the MaxCombo method. Note that the model selection bias is fully addressed by the multiplicity control in hypothesis testing: the adjusted p-value procedure preserves the type-I error. patients due to the additional data maturity described above. In contrast, in the diminishing effect scenario, HR estimates decrease as the sample size increases (and event-patient ratio decreases).
In the PH scenario (including null), sample size does not impact the HR estimate since the treatment effect is constant over time.
REAL DATA EXAMPLES
To explore alternative tests in real clinical studies, Bristol-Myers Squibb (BMS) and
AstraZeneca contributed survival datasets from two completed oncology clinical studies. The KM plots and statistical results are presented in the Appendix II. We compared the time-to-event endpoints using the datasets reconstructed (Guyot et al. 2012 ) based on the original publication between the two treatment arms using the weighted log-rank test with FH(0,1), FH(1,0), FH (1, 1) weights, the max-combo test (with set of weights of (0,0), (0,1), (1,0) and (1,1)) and the difference in RMST. Given the non-PH pattern observed, piece-wise HRs were also estimated with the underlying change point that was selected post hoc based on the KM curves. These methods were retrospectively applied in order to contrast with the results using log-rank tests and standard Cox HR estimates in the original publication. Note that results reported in the original publications were based on stratified analyses whereas our results were based on unstratified analyses. Minor differences were observed, but they will not affect the interpretation of the comparisons presented below. Non-PH was suspected based on visual inspection of the OS curves, which overlapped before 9 months and start to separate afterward, representing a typical "delayed effect" scenario. A Schoenfeld residual plot was generated (Figure 3) , which showed a potential non-random pattern over time; however, the G-T p-value (Grambsch and Therneau 1994) was not significant (p=0.142). Note that this is consistent with prior literature that shows the G-T test is not a powerful test and may fail to declare statistical significance even though PH assumption is clearly violated (Lin 2017) . Table 4 had a slightly larger p-value than the FH(0,1), due to the penalty for the multiplicity adjustment due to inclusion of all four tests. The study required 944 PFS events to have 80% power to demonstrate a noninferiority (NI) margin of 1.2 if the treatments were truly equal, with a two-sided 5% probability of incorrectly concluding NI. If NI was demonstrated, testing for superiority was conducted and the treatment was declared superior if the upper bound of the 95% CI for HR was below 1 (equivalently, the 2sided p-value was less than 0.05).
Case study 1:
Case study 2:
The study demonstrated a statistically significant PFS improvement in favor of gefitinib.
However, interestingly the PFS initially favored the chemotherapy arm, with the curves crossing at around the end of the 6th month in favor of gefitinib. The OS results also showed similar features of crossing OS curves, although the overall treatment effect was more modest and did not reach statistical significance at the time of analysis.
A Schoenfeld residual plot for PFS was generated (Figure 4 a) , which showed a non-random pattern over time (G-T p-value < 0.001) formally confirming initial observations. Similar analyses, as in PFS, were conducted for OS. Again, based on visual inspection and the Schoenfeld residual plot (Figure 4 b) , data were indicative of a lack of PH, even though the G-T test was not significant (p=0.67). Interestingly, only two of the six tests were statistically significant in this case: the FH(1,1) and
the MaxCombo (selected weight = [1, 1] ). Looking at the OS curve, it makes intuitive sense why the FH(1,1) may be statistically significant, given it puts more emphasis on events occurring in the middle part of the curve versus those happening early or late. This also demonstrates the agility of the MaxCombo test to identify different patterns of non-PH without knowing a priori which one will actually be observed. Due to the multiplicity adjustment, the p-value from the MaxCombo test is again slightly larger than the FH(1,1). Nonetheless, both tests are significant.
Given that the OS curves were crossing at approximately 8 months, and most patients were curves. However, in practice, we recommend that these change points be pre-specified in the study analysis plan based on prior knowledge about the treatment or based on clinical relevance.
The PFS or OS rates at pre-specified time-points (e.g., 6, 12 months) have simple clinical interpretation and can help describing the treatment effect through multiple time points on the Kaplan-Meier curves, which can be pre-specified based on expected study duration and clinical relevance. The difference in RMST provides a different perspective in terms of quantifying the benefit and is especially appealing since it does not assume PH. Similar to piece-wise HRs, RMST estimates can be evaluated in an ad-hoc fashion as a function of survival time to profile the characteristics of non-PH nature (Zhao et al 2016) . We recommend reporting these multiple measures in order to reflect the totality of the data and to convey to clinicians and patients a comprehensive view of the treatment effect for clinical decision making.
In addition, for studies designed for registration purposes, it is also important to communicate with health authorities in advance to align the statistical view on the potential non-PH and attain regulatory agreement on alternative tests. The current regulatory standard of binary decision making for declaring a study to be positive or negative, based on a single p-value (from the logrank test) and estimating the treatment benefit using a single summary measure (i.e., HR from the Cox model) can be problematic, when non-PH is observed. This is because in such cases the benefit is clearly non-uniform among patients. If the initial test fails to detect statistical significance, further investigation will generally be considered exploratory. In this case, an experimental molecule with still a substantial benefit for many patients will not be able to receive marketing authorization. Therefore, the need for a more powerful test, such as the MaxCombo when non-PH is expected, can be critical in establishing this initial statistical difference between the two arms. Once that difference is established, and the study is declared positive, further investigation to optimize benefit-risk is possible. Similarly, when PH is violated, a single measure such as the HR may not be adequate in describing treatment benefit and use of additional measures such as piecewise HR, milestone survival and difference in RMST can be very useful in interpreting the trial results. It is recommended to develop a comprehensive analysis plan that defines the primary test, such as MaxCombo test, and the additional sensitivity analyses to evaluate the totality of the data based on alternative tests and summary statistics as well as standard analysis methods (e.g., log-rank test and Cox model). Such analysis plan could enable better characterization of the treatments. 
